Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSP/QRH dimer for detection of biliary intra-epithelial neoplasia
NCT04304781Phase 1Terminated
- Sponsor
- Danielle Kim Turgeon
- Start
- Sep 2020
- Primary completion
- Dec 2021
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KSP-QRH-E3-IRDye800 in cholangiocarcinoma (CCA), sponsored by Danielle Kim Turgeon. Primary endpoint: Contrast in Cell Fluorescence at 2 hours. Started Sep 2020; status: terminated.
02
Drugs
KSP-QRH-E3-IRDye800
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT04304781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04304781.